{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T12:30:12Z","timestamp":1787574612161,"version":"build-2736575974"},"reference-count":27,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T00:00:00Z","timestamp":1787443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background\/Objectives: Anticoagulation in advanced chronic kidney disease (CKD) remains challenging due to limited representation in clinical trials, resulting in uncertainty regarding optimal drug selection, dosing, and monitoring strategies. Methods: We conducted a cross-sectional, web-based survey of clinicians involved in CKD care and anticoagulation prescribing. The questionnaire explored respondent characteristics, methods of renal function estimation, anticoagulant selection across common CKD scenarios, anticoagulants\u2019 dosing and monitoring practices, and approaches to anticoagulation in nephrotic syndrome. Results: Fifty-seven clinicians participated in the survey. Unfractionated heparin was the preferred agent for venous thromboembolism (VTE) prophylaxis in patients with stage 4 and 5 CKD, or on dialysis. For acute VTE treatment, anticoagulant choice varied by CKD severity, with unfractionated heparin, direct oral anticoagulants (DOACs), and low-molecular-weight heparin (LMWH) all reported to be used depending on stages of CKD. Warfarin and DOACs were commonly used for treatment of chronic VTE and atrial fibrillation (AF), with warfarin more frequently selected in patients receiving dialysis. Apixaban was the most frequently reported DOAC, typically at a dose of 2.5 mg twice daily in advanced CKD and dialysis. Renal function estimation methods varied, with Cockcroft\u2013Gault most used overall, while nephrologists more frequently reported MDRD or CKD-EPI equations. Most respondents reported not routinely monitoring DOAC levels, and the majority indicated the absence of a structured multidisciplinary team (MDT) for managing anticoagulated CKD patients. Clinical practice varied according to specialty, experience, and healthcare setting, particularly in anticoagulant selection, dosing strategies, and use of risk stratification tools. Conclusions: Anticoagulation practices in advanced CKD are highly heterogeneous, reflecting persistent evidence gaps. While unfractionated heparin and warfarin remain central in patients with stage 5 CKD or on dialysis, DOAC use\u2014particularly apixaban\u2014has expanded, often with empiric dose reduction. These findings underscore the need for clearer guidance, standardized approaches to renal function assessment, multidisciplinary care pathways, and prospective studies focusing on anticoagulation use in CKD populations.<\/jats:p>","DOI":"10.3390\/jcm15176517","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T11:47:19Z","timestamp":1787572039000},"page":"6517","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Survey on Anticoagulation Practices in Patients with Chronic Kidney Disease in Saudi Arabia"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4402-4496","authenticated-orcid":false,"given":"Mansoor","family":"Radwi","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, University of Jeddah, Jeddah 23218, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3650-7626","authenticated-orcid":false,"given":"Enad","family":"Alsolami","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, University of Jeddah, Jeddah 23218, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Hill, N.R., Fatoba, S.T., Oke, J.L., Hirst, J.A., O\u2019Callaghan, C.A., Lasserson, D.S., and Hobbs, F.D.R. (2016). Global prevalence of chronic kidney disease\u2014A systematic review and meta-analysis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0158765"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1161\/CIRCULATIONAHA.122.062752","article-title":"Direct oral anticoagulants versus warfarin across the spectrum of kidney function: Patient-level network meta-analyses from COMBINE AF","volume":"147","author":"Harrington","year":"2023","journal-title":"Circulation"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000535546","article-title":"Anticoagulation in patients with chronic kidney disease","volume":"55","author":"Elenjickal","year":"2024","journal-title":"Am. J. Nephrol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1053\/j.ajkd.2023.08.017","article-title":"Comparative safety and effectiveness of warfarin or rivaroxaban versus apixaban in patients with advanced CKD and atrial fibrillation: Nationwide US cohort study","volume":"83","author":"Fu","year":"2023","journal-title":"Am. J. Kidney Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"165","DOI":"10.7861\/clinmedicine.14-2-165","article-title":"The newer direct oral anticoagulants: A practical guide","volume":"14","author":"Thachil","year":"2014","journal-title":"Clin. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.mayocp.2023.01.007","article-title":"Oral anticoagulation in patients with advanced chronic kidney disease and atrial fibrillation: Beyond anticoagulation","volume":"98","author":"Dhaese","year":"2023","journal-title":"Mayo Clin. Proc."},{"key":"ref_7","first-page":"e32788","article-title":"Anticoagulation for stroke prevention of concomitant atrial fibrillation and end-stage renal disease: Insights of cardiologists and nephrologists from India","volume":"14","author":"Swetha","year":"2022","journal-title":"Cureus"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Parker, K., Choudhuri, S., Lewis, P., Thachil, J., and Mitra, S. (2023). UK prescribing practice of anticoagulants in patients with chronic kidney disease: A nephrology and haematology-based survey. BMC Nephrol., 24.","DOI":"10.1186\/s12882-022-03041-w"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1053\/j.ajkd.2021.08.003","article-title":"A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease","volume":"79","author":"Delgado","year":"2022","journal-title":"Am. J. Kidney Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1080\/17425255.2023.2287472","article-title":"Pharmacokinetics and pharmacodynamics of direct oral anticoagulants","volume":"19","author":"Hindley","year":"2023","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1053\/j.ajkd.2007.12.040","article-title":"Pharmacodynamics of unfractionated heparin during and after a hemodialysis session","volume":"51","author":"Brunet","year":"2008","journal-title":"Am. J. Kidney Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/ckj\/sfu080","article-title":"Anticoagulation in chronic kidney disease patients\u2014The practical aspects","volume":"7","author":"Hughes","year":"2014","journal-title":"Clin. Kidney J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s11739-008-0164-9","article-title":"Low-molecular-weight heparin in patients with chronic renal insufficiency","volume":"3","author":"Lim","year":"2008","journal-title":"Intern. Emerg. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(07)61445-7","article-title":"Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: A randomised, double-blind, non-inferiority trial","volume":"370","author":"Eriksson","year":"2007","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Yin, Q., Zheng, X., Ni, X., Wang, Y., Huang, X., Song, Y., Han, L., Huang, Y., and Bian, Y. (2025). Efficacy and safety of oral anticoagulants in the treatment of chronic kidney disease with atrial fibrillation or venous thromboembolism: A systematic review and meta-analysis. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1615284"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"151517","DOI":"10.1016\/j.semnephrol.2024.151517","article-title":"Oral anticoagulation use in individuals with atrial fibrillation and chronic kidney disease: A review","volume":"44","author":"Wing","year":"2024","journal-title":"Semin. Nephrol."},{"key":"ref_18","unstructured":"(2021). Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int., 100, S1\u2013S276."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ekir.2019.12.001","article-title":"A Systematic Review of Prophylactic Anticoagulation in Nephrotic Syndrome","volume":"5","author":"Lin","year":"2019","journal-title":"Kidney Int. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"sfaf104","DOI":"10.1093\/ckj\/sfaf104","article-title":"Prophylactic anticoagulation in patients with nephrotic syndrome in the Cure Glomerulonephropathy (CureGN) cohort","volume":"18","author":"Han","year":"2025","journal-title":"Clin. Kidney J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/ajhp\/zxab411","article-title":"Establishing a multidisciplinary taskforce to improve anticoagulation safety at a large health system","volume":"79","author":"Attia","year":"2022","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/1358863X261430616","article-title":"Clinical effectiveness of a multidisciplinary thrombosis service versus usual care in the management of venous thromboembolism: A retrospective cohort study","volume":"31","author":"Bonsu","year":"2026","journal-title":"Vasc. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ekir.2024.10.016","article-title":"Direct Oral Anticoagulants in Patients with ESRD and Kidney Transplantation","volume":"10","author":"Lange","year":"2025","journal-title":"Kidney Int. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"181","DOI":"10.7326\/M19-0087","article-title":"Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease: A Systematic Review and Meta-analysis","volume":"171","author":"Ha","year":"2019","journal-title":"Ann. Intern. Med."},{"key":"ref_26","first-page":"3314","article-title":"2024 ESC Guidelines for the management of atrial fi-brillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): Developed by the task force for the management of atrial fibrillation of the European Society of Cardi-ology (ESC), with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO)","volume":"45","author":"Rienstra","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_27","first-page":"924","article-title":"Anticoagulation for patients with atrial fibrillation and end-stage renal disease on dialysis: A national survey","volume":"37","author":"Halperin","year":"2021","journal-title":"Can. J. Cardiol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/17\/6517\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T12:08:35Z","timestamp":1787573315000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/17\/6517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,23]]},"references-count":27,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["jcm15176517"],"URL":"https:\/\/doi.org\/10.3390\/jcm15176517","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,23]]}}}